Oxurion | Evaluate

November 29, 2019

Upcoming events – Kalvista aims for acuity and a me-too from Sanofi approaches

As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.

August 20, 2019

Where now for Oxurion?

The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.

July 19, 2019

Upcoming events – catalysts approach for Catalyst and Oxurion

Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.

July 02, 2019

Bicycle continues skidding despite Oxurion’s endorsement

October 11, 2017

Kalvista leads the kallikrein eye disease pipeline

September 22, 2017

Snippet roundup: Teva and Thrombogenics get some short-term relief

December 02, 2016

Snippet roundup: Deals for Boston and Astra, data for Novo and an approval for Biosurfit

November 09, 2016

No way to bury Arrowhead and Bioinvent’s bad news

April 14, 2015

On to the curious for Thrombogenics

October 29, 2014

Poor industry scorecard drives desmoteplase rescue plan

October 06, 2014

Acquisitions help define performance of mid and small cap stocks

Load More